Ingredion Inc.’s (Westchester, IL) Hi-Maize high-amylose maize resistant starch has a newly approved qualified health claim from FDA linking the ingredient with a reduction in the risk of type 2 diabetes.
Foods and beverages—including bakery, nutrition bar, and cereal and pasta products—using Hi-Maize can now use the claims:
- “High-amylose maize resistant starch may reduce the risk of type 2 diabetes. FDA has concluded that there is limited scientific evidence for this claim.”
- “High-amylose maize resistant starch, a type of fiber, may reduce the risk of type 2 diabetes. FDA has concluded that there is limited scientific evidence for this claim.”
According to Ingredion, FDA based its assessment on eight clinical trials showing the positive impact of Hi-Maize on insulin sensitivity and other biomarkers related to blood sugar.
“We believe the new qualified health claim is a positive development for consumers as it provides another pragmatic approach to potential diabetes risk reduction through everyday foods,” said Lorraine Niba, PhD, global director, nutrition springboard, for Ingredion.